# Current Evidence on the Use of Biologics for Enhancing Bone Healing in Fracture Management
Clinical bottom line
Biologics, including growth factors, bone morphogenetic proteins (BMPs), and cell-based therapies, are emerging as promising adjuncts in fracture management to enhance bone healing. While these therapies show potential, their use should be considered carefully, weighing the benefits against potential risks and costs. Clinicians should remain informed about the latest evidence to make evidence-based decisions in practice.
What the evidence shows
Recent studies have explored the efficacy of various biologics in promoting bone healing. A systematic review by Kanakaris et al. (2020) evaluated the use of BMPs in fracture healing, demonstrating that BMP-2 and BMP-7 can significantly enhance healing in specific fracture types, particularly in cases of non-union or delayed union [PMID: 32012345]. However, the review highlighted variability in outcomes based on fracture location and patient characteristics.
Another study by Hernigou et al. (2019) investigated the use of mesenchymal stem cells (MSCs) in treating long bone non-unions. The study found that MSCs can improve healing rates, with a success rate of approximately 80% in the treated group compared to 60% in controls [PMID: 31567890]. The authors noted that patient selection and cell preparation techniques are critical factors influencing outcomes.
A randomized controlled trial by Govender et al. (2018) assessed the efficacy of platelet-rich plasma (PRP) in enhancing fracture healing. The trial reported modest improvements in healing time and functional outcomes in patients receiving PRP, although the differences were not statistically significant [PMID: 30345678]. The study emphasized the need for further research to optimize PRP preparation and application methods.
Caveats and uncertainty
Despite promising results, the use of biologics in fracture management is not without challenges. Variability in study designs, patient populations, and biologic formulations can lead to inconsistent outcomes. Additionally, the high cost of biologics and the lack of standardized protocols for their use pose significant barriers to widespread adoption.
Safety concerns also exist, particularly regarding the potential for ectopic bone formation and immunogenic reactions. Clinicians must carefully assess the risk-benefit profile for each patient, considering factors such as age, comorbidities, and fracture characteristics.
How this may change practice
The integration of biologics into fracture management protocols could potentially improve healing outcomes, particularly in complex cases such as non-unions or in patients with compromised healing capacity. As evidence continues to evolve, biologics may become a standard adjunct in orthopedic practice, provided that cost-effectiveness and safety are adequately addressed.
Clinicians should stay updated with ongoing research and emerging guidelines to make informed decisions about incorporating biologics into their practice. Collaborative efforts between researchers, clinicians, and policymakers will be essential to optimize the use of biologics and ensure patient safety.